KEAP1 and non-small cell lung carcinoma: The Keap1 mutation was identified in 2/76 (2.6%) NSCLC patients (Fig. 1); 1 A191P (571 G to C, alanine to proline; stage IIIa) and 1 E218Q (652 G to T, glutamate to glutamine; stage IIb).